China Resources Sanjiu
华润三九
Executive Summary
China Resources Sanjiu is a major Chinese pharmaceutical company listed on the Shenzhen Stock Exchange with strong financial performance, reporting revenue of ~RMB 27.6B and net profit of ~RMB 3.4B in 2024. The company is clear of BIOSECURE designation and appears to maintain strong governance standards with recent ESG reporting and independent director oversight. As a subsidiary of state-owned China Resources Group, it represents a relatively stable and compliant partner for US BD teams, though its therapeutic focus areas and pipeline depth remain unclear from available data.
Structure: China Resources Sanjiu operates as a publicly-listed subsidiary under the China Resources Group, a major Chinese state-owned conglomerate. The company maintains standard Chinese corporate governance structures with independent directors and regular financial reporting, suggesting relatively straightforward due diligence processes compared to VIE structures.
Latest Financials
Revenue: 27616611772.61, Net Profit: 3367888968.2. Source: East Money (000999)
Period: 2024-12-31 | Source: eastmoney
Corporate Events
华润三九：2025年可持续发展暨ESG报告（英文版）
CNINFO announcement for China Resources Sanjiu (000999.SZ)
华润三九：独立董事2025年度述职情况报告（孙健）
CNINFO announcement for China Resources Sanjiu (000999.SZ)
华润三九：2025年年度报告摘要
CNINFO announcement for China Resources Sanjiu (000999.SZ)
华润三九：2025年年度审计报告
CNINFO announcement for China Resources Sanjiu (000999.SZ)
华润三九：关于与广东华润银行开展业务合作的关联交易公告
CNINFO announcement for China Resources Sanjiu (000999.SZ)
China Resources Sanjiu Financial Report
Revenue: 27616611772.61, Net Profit: 3367888968.2. Source: East Money (000999)
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating minimal regulatory risk for US partnerships
Key Exposures:
- •State ownership through China Resources Group could create future scrutiny
- •Standard risks associated with Chinese pharmaceutical companies
Mitigation: Company appears compliant with transparency requirements through regular ESG reporting and governance disclosures
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing activity identified in available data
Approach: Engage through formal channels given state ownership structure; focus on understanding therapeutic portfolio and R&D capabilities before pursuing partnerships
Red Flags
- ⚠Lack of available pipeline or therapeutic area information
- ⚠Limited visibility into key management team
- ⚠No clear subsidiary structure disclosed
- ⚠Absence of recent international partnership activity
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 6
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.